Articles about 'Tony Kouzarides'

10 Cambridge spinouts on putting their research into practice to improve outcomes for cancer patients - and why Cambridge is a great place to do this.    

The facility, based at the Milner Therapeutics Institute, will support the discovery of new medicines and diagnostics for chronic diseases by applying advanced biological and technological tools, including CRISPR gene editing.

Co-founder and CEO of Start Codon, Jason Mellad on helping healthcare start-ups thrive and why inclusion and diversity will change the world.

Connect: Health Tech, the University of Cambridge Enterprise Zone, has today launched a roadmap, ‘Creating a University Enterprise Zone for Cambridge across the life and physical sciences’, that examines the challenges faced in futureproofing and sustaining the growth of the life sciences cluster to maintain Cambridge as a global centre of excellence for health tech.

Cambridge scientists have identified 200 approved drugs predicted to work against COVID-19 – of which only 40 are currently being tested in COVID-19 clinical trials.

Scientists have made a promising step towards developing a new drug for treating acute myeloid leukaemia, a rare blood disorder. In a study published today in Nature, Cambridge researchers report a new approach to cancer treatment that targets enzymes which play a key role in translating DNA into proteins and which could lead to a new class of cancer drugs.

Tony Kouzarides is passionate about ecosystems: well-balanced communities that flourish on mutual and dynamic interactions. But the ecosystems that excite him are not made up of plants, animals and environments. They’re made up of experts.

An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of developing and studying precision medicines for some of the most globally devastating diseases.

Six Cambridge researchers are among the 44 new Fellows announced by the Royal Society this week.

New drug could treat mixed-lineage leukaemia (MLL).